


Cadmium-Free Sugar-Chain-Immobilized Fluorescent Nanoparticles Containing Low-Toxicity ZnS-AgInS₂ Cores for Probing Lectin and Cells

Hiroyuki Shinchi,[†] Masahiro Wakao,^{*,†} Nonoka Nagata,[†] Masaya Sakamoto,[†] Eiko Mochizuki,[‡] Taro Uematsu,[‡] Susumu Kuwabata,[‡] and Yasuo Suda^{*,†,§}

[†]Department of Chemistry, Biotechnology and Chemical Engineering, Graduate School of Science and Engineering, Kagoshima University, 1-21-40 Kohrimoto, Kagoshima 890-0065, Japan

[‡]Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan

[§]SUDx-Biotec Corporation, 1-42-1 Shiroyama, Kagoshima 890-0013, Japan



ABSTRACT: Sugar chains play a significant role in various biological processes through sugar chain–protein and sugar chain–sugar chain interactions. To date, various tools for analyzing sugar chains biofunctions have been developed. Fluorescent nanoparticles (FNPs) functionalized with carbohydrate, such as quantum dots (QDs), are an attractive imaging tool for analyzing carbohydrate biofunctions in vitro and in vivo. Most FNPs, however, consist of highly toxic elements such as cadmium, tellurium, selenium, and so on, causing problems in long-term bioimaging because of their cytotoxicity. In this study, we developed cadmium-free sugar-chain-immobilized fluorescent nanoparticles (SFNPs) using ZnS-AgInS₂ (ZAIS) solid solution nanoparticles (NPs) of low or negligible toxicity as core components, and investigated their bioavailability and cytotoxicity. SFNPs were prepared by mixing our originally developed sugar-chain-ligand conjugates with ZAIS/ZnS core/shell NPs. In binding experiments with lectin, the obtained ZAIS/ZnS SFNPs interacted with an appropriate lectin to give specific aggregates, and their binding interaction was visually and/or spectroscopically detected. In addition, these SFNPs were successfully utilized for cytometry analysis and cellular imaging in which the cell was found to possess different sugar-binding properties. The results of the cytotoxicity assay indicated that SFNPs containing ZAIS/ZnS have much lower toxicity than those containing cadmium. These data strongly suggest that our designed SFNPs can be widely utilized in various biosensing applications involved in carbohydrates.

INTRODUCTION

Cell-surface sugar chains play a significant role in a variety of biological events, such as cell–cell recognition, proliferation, differentiation, immune response, signal transduction, and infection.^{1,2} The specific binding interaction between sugar chains and proteins, and sometimes between sugar chains and sugar chains, is the initiating point of these events. Analysis of the binding interaction at the molecular level therefore leads us not only toward a better understanding of these biofunctions, but also toward new biological insights involving sugar chains. Numerous efforts have been devoted to sugar-chain structure–function analysis, and many techniques like sugar chain array, chips, fluorescent probes, and nanoparticles have been developed.^{3–22}

Nowadays, sugar chains are considered new biomarkers for determining cell type,^{1,2,23–25} similar to nucleic acids and proteins,^{26–28} since the glycosylation pattern on the cell surface

varies depending on the tissue and cell type. Glycomic analysis of the cell is therefore a valuable approach for knowing cell status. Lectin-based profiling is a useful method for determining cell status and has been investigated in various cells like embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, tumor cells, and other cultivated cell lines.^{29–32} Sugar-chain-based profiling is a promising approach because the recognition ability of cells for sugar-chain changes depending on the cell conditions and provides information regarding the cell status, and is applicable to the evaluation of the metastatic property of tumor cells and quality control of cultivated cells.

Sugar-chain-immobilized fluorescent nanoparticles (SFNPs) are an attractive biosensing tool for the analysis of sugar chain

Received: September 17, 2013

Revised: January 14, 2014

Published: January 19, 2014

biofunctions.^{16–22} Quantum dots (QDs) are often utilized as core components and have been extensively investigated as a fluorescent probe for biomedical imaging and diagnosis.^{33–37} Therefore, various SFNPs containing QDs have been synthesized and their biological applications explored. Most QDs contains cadmium ions, which is often problematic in vivo and/or in vitro bioassays because of their cytotoxic activity.^{38–42} In order to suppress the cytotoxicity of cadmium ions, coating with a low-toxicity ZnS shell or various polymers has been utilized. However, it is difficult to completely abrogate the cytotoxicity of cadmium ions because these ions are released from nanoparticles by lysosomal degradation processes, photolysis, and oxidation.^{39,43–46}

In this paper, we report the synthesis of cadmium-free SFNP using low-toxicity ZnS-AgInS₂ (ZAIS)/ZnS NPs. Immobilization of the sugar chain moiety was accomplished by a simple ligand exchange reaction using our ligand conjugates, in which various sugar-chain structures were conjugated with a thioctic acid moiety via a linker molecule. Carbohydrate–lectin interaction using our SFNPs was detected spectroscopically or visually. Flow cytometry analysis and fluorescent imaging of cells was also performed, and the results clarified that the binding property of cell for a sugar chain is different depending on the cell type. Furthermore, in the cytotoxicity assay, SFNPs containing ZAIS/ZnS NPs were found to be much less toxic than those containing CdTe/CdS QDs.

■ EXPERIMENTAL PROCEDURES

Materials. All chemical reagents were commercial grade except as noted. Thioglycolic acid (TGA, purity: 90%), 3-mercaptopropionic acid (3-MPA, purity: 98%), NaBH₄ (purity: >95.0%), KOH (purity: >85%), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and trypan blue solution (0.5%) were purchased from Nacalai Tesque (Kyoto, Japan). Thioacetamide (purity: >99.0%), zinc acetate anhydrate (purity: 99.99%), RPMI1640 medium, and Dulbecco's modified Eagle's medium (DMEM) were purchased from Sigma Aldrich (St. Louis, MO, USA). Indium(III) nitrate trihydrate (purity: >98.0%), silver nitrate (purity: 99.9%), sodium *N,N*-diethyldithiocarbamate trihydrate (purity: >90%), and zinc nitrate hexahydrate (99.9%) were purchased from Wako (Osaka, Japan). Oleylamine (purity: >40%) was purchased from TCI (Tokyo, Japan). Concanavalin A (Con A), Ricin communis agglutinin I (RCA120), and bovine serum albumin (BSA) were purchased from Seikagaku Corporation (Tokyo, Japan), Vector Laboratories (Burlingame, CA, USA), and Nacalai Tesque, respectively. Fetal bovine serum (FBS) was purchased from Nichirei (Tokyo, Japan). Penicillin streptomycin (PS) was purchased from GIBCO (Carlsbad, CA, USA). Milli-Q water (18.2 MΩ cm⁻¹) was used in all experiments unless otherwise noted. Sugar chain–ligand conjugates^{47,48} and SFNPs containing CdTe/CdS⁴⁹ were prepared using previously reported methods.

Measurements. UV/vis spectra and fluorescence spectra were measured using a V-650 spectrometer and an FP-6310 fluorescence spectrometer (JASCO, Tokyo, Japan), respectively. Mass spectra were measured using the Voyager-DE-PRO (Applied Biosystems, Foster City, CA, USA) or micrOTOF II (Bruker Daltonics, Billerica, MA, USA). Flow cytometry analyses were performed using the Cytomics FC 500 Cytometer (Beckman Coulter, Brea, CA, USA). Fluorescence imaging data were obtained using a Nikon A1si-90i (Nikon, Tokyo, Japan). Colorimetric MTT assay was performed using

an Immuno Mini NJ-2300 (MICROTEC, Chiba, Japan). Stained cells were observed using an inverted microscope CKX-31 (Olympus, Tokyo, Japan).

Preparation of Sugar-Chain–Ligand Conjugates. Sugar-chain–ligand conjugates were prepared by the method reported previously.^{47,48} Oligosaccharides used were commercially available or from a synthetic source. Briefly, a mixture of oligosaccharide and linker moiety in DMAc/H₂O/AcOH (10:10:1) was left at 40 °C. After 5 h, NaBH₃CN was added to the mixture and the reaction mixture was left at 40 °C again. After 3 days, the reaction mixture was lyophilized. The residue was then purified by reversed-phase silica gel column chromatography (eluent: H₂O/MeOH gradient system) to yield the sugar-chain–ligand conjugate.

N-[3-[(2-Deoxy-2-acetamido- α -D-glucopyranosyl)-(1–4)-(1-deoxy-D-glucitol-1-yl)amino]phenyl]-DL- α -lipoamide (GlcNAc α 1–6Glc-mono, 3). ¹H NMR (600 MHz, D₂O) δ 7.019 (1H, t, *J* = 8.2 Hz, aromatic), 6.78 (1H, s, aromatic), 6.65 (1H, d, *J* = 8.2 Hz, aromatic), 6.38 (1H, d, *J* = 8.2 Hz, aromatic), 4.61 (1H, d, *J*_{1',2'} = 3.4 Hz, H-1'), 3.76 (1H, ddd, *J*_{2,3} = 6.8 Hz, *J*_{2,1a} = 5.4 Hz, *J*_{2,1b} = 4.8 Hz, H-2), 3.73–3.60 (5H, m, H-3, H-5, H-6a, H-2', H-6a'), 3.55–3.49 (5H, m, H-4, H-3', H-5', H-6b', -SSCH₂CH₂CH=), 3.39 (1H, d, *J*_{6a,6b} = 8.2 Hz, H-6b), 3.23 (1H, dd, *J*_{4',3'} = 8.8 Hz, *J*_{4',5'} = 9.5 Hz, H-4'), 3.17 (1H, dd, *J*_{1a,2} = 4.8 Hz, *J*_{1a,1b} = 8.8 Hz, H-1a), 3.07 (1H, ddd, *J* = 10.7 Hz, 6.1 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 3.01 (1H, ddd, *J* = 11.3 Hz, 6.8 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 2.94 (1H, dd, *J*_{1b,2} = 5.4 Hz, *J*_{1b,1a} = 8.2 Hz, H-1b), 2.32 (1H, dddd, *J* = 12.7 Hz, 6.1 Hz, 6.1 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 2.22 (2H, t, *J* = 7.48 Hz, -NHCOCH₂-), 1.83 (3H, s, -COCH₃), 1.82–1.78 (1H, m, -SSCH₂CH₂CH=), 1.64–1.59 (1H, m, -NHCOCH₂CH₂-), 1.55–1.44 (3H, m, -NHCOCH₂CH₂-, -NHCOCH₂CH₂CH₂CH₂CH₂-), 1.34–1.27 (2H, m, -NHCOCH₂CH₂CH₂-); HRMS (positive mode); Found: *m/z* 686.2391 [(M+Na)⁺], Calcd. for C₂₆H₄₂N₂O₁₁S₂Na: 686.2388.

N-[3-[(α -D-Mannopyranosyl)-(1–4)-(1-deoxy-D-glucitol-1-yl)amino]phenyl]-DL- α -lipoamide (Man α 1–6Glc-mono, 4). ¹H NMR (600 MHz, D₂O) δ 7.20 (1H, t, *J* = 8.2 Hz, aromatic), 6.95 (1H, s, aromatic), 6.85 (1H, *J* = 7.5 Hz, d, aromatic), 6.58 (1H, d, *J* = 7.5 Hz, aromatic), 4.82 (1H, s, H-1'), 3.97–3.92 (1H, ddd, *J*_{2,3} = 7.7 Hz, *J*_{2,1a} = 4.1 Hz, *J*_{2,1b} = 4.1 Hz, H-2), 3.92–3.88 (1H, m, H-2'), 3.88–3.80 (4H, m, H-3, H-6a, H-6a', H-6b'), 3.80–3.76 (1H, dd, *J*_{3',4'} = 6.1 Hz, *J*_{3',2'} = 3.4 Hz, H-3'), 3.73–3.59 (6H, m, H-4, H-5, H-6b, H-4', H-5', -SSCH₂CH₂CH=), 3.35 (1H, dd, *J*_{1a,2} = 4.1 Hz, *J*_{1a,1b} = 9.5 Hz, H-1a), 3.25 (1H, ddd, *J* = 10.1 Hz, 6.8 Hz, 6.8 Hz, -SSCH₂CH₂CH=), 3.19 (1H, ddd, *J* = 10.1 Hz, 6.8 Hz, 6.8 Hz, -SSCH₂CH₂CH=), 3.16–3.11 (1H, dd, *J*_{1b,1a} = 8.2 Hz, *J*_{1b,2} = 5.4 Hz, H-1b), 2.50 (1H, dddd, *J* = 12.3 Hz, 6.1 Hz, 6.1 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 2.40 (2H, t, *J* = 6.8 Hz, -NHCOCH₂-), 2.00 (1H, dddd, *J* = 12.3 Hz, 6.1 Hz, 6.1 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 1.82–1.76 (1H, m, -NHCOCH₂CH₂-), 1.76–1.64 (3H, m, -NHCOCH₂CH₂CH₂CH₂CH₂-, -NHCOCH₂CH₂CH₂CH₂CH₂CH₂CH₂CH₂-), 1.53–1.47 (2H, m, -NHCOCH₂CH₂CH₂-); HRMS (positive mode); Found: *m/z* 645.2126 [(M+Na)⁺], Calcd. for C₂₆H₄₂N₂O₁₁S₂Na: 645.2122.

N-[3-[(5-Acetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosidonic acid)-(2–3)-(α -D-galactopyranosyl)-(1–4)-(1-deoxy-D-glucitol-1-yl)amino]phenyl]-DL- α -lipoamide (SA α 2–3Gal β 1–4Glc-mono, 5). ¹H NMR (600 MHz, D₂O) δ 7.40 (1H, t, *J* = 8.2 Hz, aromatic), 7.34

(1H, s, aromatic), 7.21 (1H, d, $J = 8.2$ Hz, aromatic), 6.90 (1H, d, $J = 8.2$ Hz), 7.41–6.90 (4H, m, aromatic), 4.58 (1H, dd, $J_{1',2'} = 7.5$ Hz, H-1'), 4.09–4.08 (2H, m, H-2, H-3'), 3.96–3.58 (18H, m, H-3, H-4, H-5, H-6a, H-6b, H-2', H-4', H-5', H-6a', H-6b', H-4'', H-5'', H-6'', H-7'', H-8'', H-9a'', H-9b'', -SSCH₂CH₂CH=), 3.52–3.49 (1H, m, H-1a), 3.37–3.26 (2H, m, H-1b, -SSCH₂CH₂CH=), 3.23 (1H, ddd, $J = 11.3$ Hz, 6.8 Hz, 6.8 Hz, -SSCH₂CH₂CH=), 2.78–2.76 (1H, m, H-3a''), 2.59–2.52 (1H, m, -NHCOCH₂CH₂-), 2.47 (2H, t, $J = 6.8$ Hz, NHCOCH₂CH₂-), 2.06 (3H, s, -COCH₃), 2.05–2.01 (1H, m, -SSCH₂CH₂CH=), 1.83–1.71 (5H, m, H-3b'', -NHCOCH₂CH₂-), -NHCOCH₂CH₂CH₂CH₂-), 1.55–1.53 (2H, m, -NHCOCH₂CH₂CH₂-); ESI-MS (positive mode); Found: m/z 958.2894 [(M+2Na)⁺], Calcd. for C₃₇H₅₈N₃O₁₉S₂Na₂: 958.2896.

N-[3-[(5-Acetamido-3,5-dideoxy-D-glycero- α -D-galacto-2-nonulopyranosidonic acid)-(2-6)-(α -D-galactopyranosyl)-(1-4)-(1-deoxy-D-glucitol-1-yl)amino]phenyl]-DL- α -lipoamide (SA α 2-6Gal β 1-4Glc-mono, 6). ¹H NMR (600 MHz, D₂O) δ 7.28 (1H, t, $J = 7.5$ Hz, aromatic), 7.25–7.23 (2H, m, aromatic), 6.71 (1H, d, $J = 6.8$ Hz, aromatic), 4.47 (1H, d, $J_{1',2'} = 8.2$ Hz, H-1'), 4.04 (1H, m, H-2), 3.93–3.52 (19H, m, H-3, H-4, H-5, H-6a, H-6b, H-2', H-3', H-4', H-5', H-6a', H-6b', H-4'', H-5'', H-6'', H-7'', H-8'', H-9a'', H-9b'', -SSCH₂CH₂CH=), 3.43 (1H, dd, $J_{1a,1b} = 8.8$ Hz, $J_{1a,2} = 4.1$ Hz, H-1a), 3.31–3.29 (2H, m, H-1b, -SSCH₂CH₂CH=), 3.24 (1H, ddd, $J = 10.7$ Hz, 6.8 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 2.75–2.72 (1H, m, H-3a''), 2.55 (1H, dddd, $J = 12.3$ Hz, 6.1 Hz, 6.1 Hz, 6.1 Hz, -SSCH₂CH₂CH=), 2.45 (2H, t, $J = 6.8$ Hz, -NHCOCH₂-), 2.06 (3H, s, -COCH₃), 2.04–2.02 (1H, m, -NHCOCH₂CH₂-), 1.82–1.76 (1H, m, -NHCOCH₂CH₂-), 1.86–1.69 (4H, m, H-3b'', -NHCOCH₂CH₂-), -NHCOCH₂CH₂CH₂CH₂-), 1.55–1.53 (2H, m, -NHCOCH₂CH₂CH₂-); HRMS (positive mode); Found: m/z 958.2892 [(M+2Na)⁺], Calcd. for C₃₇H₅₈N₃O₁₉S₂Na₂: 958.2896.

Preparation of ZAIS/ZnS NPs. Hydrophobic ZAIS/ZnS core/shell NPs were prepared according to the method reported by Torimoto et al.^{50,51} The ZAIS core was prepared by thermal decomposition of a metal ion-diethyldithiocarbamate complex of (AgIn)_xZn_{2(1-x)}(S₂CN(C₂H₅)₂)₄. Briefly, the complex powder was prepared by mixing 50 mL of a sodium diethyldithiocarbamate aqueous solution (50 mM) with 50 mL of an aqueous solution containing silver nitrate, indium nitrate, and zinc nitrate at a molar ratio of $x:x:2(1-x)$ (total concentration of metal ions: 25 mM) followed by washing with methanol several times and drying under vacuum. The complex powder (50.0 mg) was placed in a two-necked flask and heat-treated at 180 °C for 30 min in Ar atmosphere. Then, oleylamine (3 mL) was added to the obtained brown powder, followed by further heat treatment under vigorous stirring at 180 °C for 5 min in Ar atmosphere. The resulting suspension was subjected to centrifugation (4000 \times g, 5 min) to remove large particles. ZAIS NPs were precipitated by the addition of methanol. Oleylamine (2 mL) was then added to the obtained precipitates. After the appropriate amounts of zinc acetate and thioacetamide at a molar ratio of 1:1 ($x = 0.9$: 56.3 μ mol; $x = 0.6$: 46.1 μ mol; $x = 0.4$: 34.8 μ mol) were added, the mixture was heated at 180 °C for 30 min in Ar atmosphere to cover with the ZnS shell. The ZAIS/ZnS core/shell NPs were precipitated by the addition of methanol. The wet precipitates were dissolved in chloroform (12 mL) to give a solution of hydrophobic ZAIS/ZnS NPs.

Next, hydrophobic NPs were converted to hydrophilic NPs. To a mixture of 3-MPA solution in ethanol (200 mM, 1 mL) and KOH solution in ethanol (300 mM, 1 mL) the NPs chloroform solution (2 mL) was added at 0 °C. The mixture was then stirred at the same temperature for 3 h in the dark. The resulting precipitates were collected by centrifugal separation (4000 \times g, 5 min). The precipitates were dissolved in water (2.0 mg/mL). The concentration of NPs was estimated from the absorbance at 360 nm. The obtained hydrophilic 3-MPA-capped ZAIS/ZnS NPs were treated with a solution of zinc acetate, thioacetamide, and TGA, sequentially. Zinc acetate, thioacetamide, and TGA were dissolved in water (2 mL) at a molar ratio of 1:1:1 ($x = 0.9$: 56.3 μ mol; $x = 0.6$: 46.1 μ mol; $x = 0.4$: 34.8 μ mol). The pH of the mixture was adjusted to 9 with NaOH (1.0 M). The hydrophilic ZAIS/ZnS NPs solution (2 mL) was added to the mixture. The reaction mixture was stirred and heated at 80 °C for 5 h under open-air conditions. After cooling, the resulting solution was diluted with water and its concentration adjusted to 0.5 mg/mL.

Immobilization of Sugar Chain onto ZAIS/ZnS NPs.

The solution of ZAIS/ZnS NPs (0.5 mg/mL, 200 μ L) was concentrated by centrifugal filtration (12 000 \times g, 5 min) using an Amicon Ultra 10K (Millipore, Billerica, MA, USA). The NPs were washed with water (100 μ L \times 2) and resuspended in water (100 μ L). In another microtube, sugar chain–ligand conjugates (50 mM, 50 μ L) and NaBH₄ aq. solution (500 mM, 50 μ L) were mixed at room temperature and the mixture was left for 10 min. The obtained solutions (each 100 μ L) were then mixed and heated for 2 h in the dark at 50 °C. Excess unreacted ligand conjugates were removed by centrifugal filtration (14 000 \times g, 5 min) using an Amicon Ultra 10K, and the residue was washed with water 3 times; then, PBS was added to prepare the SFNP solution.

Analysis of the Interaction between Proteins and Sugar Chains on SFNPs. The proteins, Con A, RCA120, or BSA, dissolved in PBS, were diluted sequentially. Fifty microliters of the resulting protein solution (20 μ M) was placed in each well of a 96-well plate. Fifty microliters of the colloidal solution (0.5 mg/mL) was then added to the wells containing the 20 μ M protein solution. After gentle agitation for 1 h, the fluorescent spectrum of the supernatant from each well was measured.

Uptake of SFNPs into Cells. THP-1 cells were placed in a cell culture flask (BD Falcon, Franklin Lakes, NJ, USA) and cultivated at 37 °C under 5% CO₂ in RPMI1640 medium containing 10% FBS and 1% PS. J774.A1 cells and HepG2 cells were placed in a cell culture flask and cultivated at 37 °C under 5% CO₂ in DMEM containing 10% FBS and 1% PS, respectively. HepG2 cells were subcultured when monolayers were 70% confluent by treatment with 0.05% trypsin containing 2 mM EDTA and then collected. For flow cytometry analysis using THP-1 and J774.A1, 5 \times 10⁵ cells (1 mL) were placed in microtubes and incubated in 150 μ L of fresh medium (FBS- and PS-free) containing SFNPs (concentration: 100 μ g/mL). After 3 h incubation at 37 or 4 °C, the medium was removed. The cells were washed with PBS (1 mL) 3 times and subjected to flow cytometry analysis. In the case of HepG2, 5 \times 10⁵ cells were placed in 12-well plate and incubated at 37 °C. After 48 h incubation, the medium was removed and 350 μ L of fresh medium (FBS- and PS-free) containing SFNPs (concentration: 100 μ g/mL) were added. After incubation for an additional 3 h at 37 or 4 °C, the medium was removed. The cells were washed with PBS (1 mL) 3 times, collected by a cell scraper (Iwaki,

Tokyo, Japan), and subjected to flow cytometry analysis. Data were accumulated using a FACS cytometer (Cytomics FC500 Cytometer). The excitation wavelength was 488 nm. Cells were gated for living cells. Fluorescence channel FL-4 was used to detect SFNP uptake by the cells. For microscopic imaging, 5×10^4 HepG2 cells were seeded in 8-well glass chamber slides. After 48 h incubation at 37 °C, the medium was removed and 100 μ L of fresh medium (FBS- and PS-free) containing SFNPs (100 μ g/mL) was added. After 3 h incubation at 37 °C, the cells were washed with PBS 3 times and a coverslip was placed on top of the cells. The slides were immediately observed using confocal laser scanning microscopy.

Cytotoxicity Assay of SFNPs. The cytotoxicity of SFNPs was evaluated by the MTT assay⁵² and trypan blue assay with ZAIS/ZnS SFNPs and CdTe/CdS SFNPs. For the MTT assay, 1×10^5 HepG2 cells (1 mL) were placed in a 24-well plate and cultivated at 37 °C under 5% CO₂ for 24 h. The cells were then placed in fresh medium (200 μ L) containing various concentrations of SFNPs (5, 25, 50, 100 μ g/mL). After 24 h incubation, the cells were washed with PBS (200 μ L \times 3). One hundred microliters of MTT solution (5 mg/mL) were added to each well and incubated for an additional 4 h at 37 °C. The medium was removed and 1 mL of DMSO was added to each well to dissolve the MTT formazan product. After agitating for 1 h, the supernatant was recovered and the amount of MTT formazan was determined by measuring the absorbance at 540 nm using Immuno Mini NJ-2300.

For the trypan blue assay, 1×10^6 J774.A1 cells were placed in a microtube and incubated in fresh medium (200 μ L) containing various concentrations of SFNPs (5, 25, 50, 100, 250 μ g/mL). After 24 h incubation, 10 μ L of cell suspension were transferred to a 200 μ L microtube and incubated for 3 min at room temperature with an equal volume of 0.5% (w/v) trypan blue staining solution. The percentage of cell viability was determined by microscopic observation using an Olympus CKX-31 microscope with a dual-chamber hemocytometer.

For the observation of cellular morphology, 1×10^5 HepG2 cells (200 μ L) were placed in 8-well glass chamber slides and cultivated for 48 h at 37 °C. The cells were placed in fresh medium (200 μ L) containing various concentrations of SFNPs (5, 50 μ g/mL). After 24 h incubation at 37 °C, the cells were washed with PBS (200 μ L \times 3), treated with a 4% formaldehyde aqueous solution for 15 min at 4 °C, and washed with PBS (200 μ L \times 3) again. Microscopic images were obtained using Eclipse 90i.

RESULTS AND DISCUSSION

Preparation of SFNPs Containing ZAIS/ZnS. Several methods for the preparation of cadmium-free fluorescent nanoparticles, such as ZnS,⁵³ CuInS₂,^{54–56} ZAIS,^{50,51} and InP,^{57,58} have been reported. In particular, ZAIS/ZnS core/shell NPs reported by Torimoto and co-workers showed attractive optical properties and high quantum yields (up to 80%). In addition, the emission color is tunable from green to red depending on their chemical composition, and no highly toxic element was contained in their components.

The chemical formula of ZAIS is Zn_{2(1-x)}(AgIn)_xS₂. The photoluminescence property of ZAIS is controllable by changing the x value. In this study, we prepared ZAIS NPs with $x = 0.9$, which gives an emission peak at around 650 nm (excitation wavelength: 360 nm). The synthesis of ZAIS/ZnS core-shell NPs was carried out according to the method reported by Torimoto and co-workers, in which oleylamine was

temporally coated on the NP surface.^{50,51} The hydrophobic oleylamine-coated ZAIS/ZnS NPs were then converted to hydrophilic NPs by treatment with 3-MPA in EtOH, followed by sequential treatment with zinc acetate, thioacetamide, and thiogluturic acid (TGA) in water at 80 °C, affording TGA-capped ZAIS/ZnS NPs. Immobilization of sugar chains onto TGA-capped ZAIS/ZnS NPs was performed by a simple ligand-exchange reaction using our original sugar chain–ligand conjugates under reductive conditions with NaBH₄ (Figure 1).⁴⁹ The optimum concentration of sugar chain–ligand




Figure 1. Preparation of SFNPs.

conjugate was examined with Glc α 1–4Glc-mono ligand conjugates (**1**), which exhibited a plateau at 10–12.5 mM of the ligand conjugate (Figure 2A). The number of sugar-chain molecules per particle was estimated to be about 320 by analysis using the anthrone-sulfuric acid method,⁵⁹ which was higher than the theoretical value⁶⁰ (the number of thioctic acid as a bidentate ligand: 130 per particle; particle diameter: 4.0 nm). It is strongly suggested that most of the ligand conjugates monovalently bind to the NP surface by the treatment of excess amounts of ligand conjugates. Immobilization of the sugar moiety was qualitatively confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis as shown in Figure 2B. A corresponding mass peak (m/z) of the used ligand conjugate was observed. The size of the obtained SFNPs was determined by transmission electron microscopy (TEM) and dynamic light scattering (DLS) analysis (Figure 2C and D). Other ligand conjugates (Gal β 1–4Glc-mono [**2**], GlcNAc α 1–6Glc-mono [**3**], Man α 1–6Glc-mono [**4**], SA α 2–3Gal β 1–4Glc-mono [**5**], and SA α 2–6Gal β 1–4Glc-mono [**6**]) (Figure 3) were used for similarly immobilizing sugar chains onto ZAIS/ZnS NPs. All these SFNPs exhibited significant stability and high dispersibility in water or phosphate-buffered saline (PBS). Lyophilized SFNPs could be stored for at least several months in a cold chamber under dark conditions (data not shown).

Binding Experiments of SFNPs with Lectins. It is known that the interaction between sugar-chain immobilized nanoparticles and proteins possessing multiple sugar-binding sites yields aggregates and can be detected visually and spectroscopically.^{19,49,61} The binding analysis of SFNPs containing ZAIS/ZnS NPs with proteins was shown in Figure 4. The proteins used were Con A (α -glucose- and α -mannose-specific), RCA120 (β -galactose-specific), and BSA (no specific binding to sugar chain). In the case of SFNPs immobilized with α Glc (α Glc-SFNP), aggregates were obtained only in the case of Con A, but not with RCA120 or BSA. When SFNPs immobilized with α GlcNAc (α GlcNAc-SFNP) were used, aggregates occurred similarly to the case of α Glc-SFNP. This result is reasonable in that the functional group at the 2-position on α -gluco- or α -mannopyranose ring does not affect the recognition of Con A. In the case of SFNPs immobilized with β Gal (β Gal-SFNP), aggregates were obtained in the case of RCA120, but not with Con A or BSA. On the other hand,




Figure 5. Flow cytometry analysis. The histogram of each cell incubated at 37 °C (left) or 4 °C (right) (A) and relative mean fluorescence intensity (MFI, B). The excitation wavelength in the FACS experiment was 488 nm. Cells were gated on living cells and FL-4 was used as a fluorescence channel to detect each cell labeled with SFNPs.

when TGA capped ZAIS/ZnS NPs were mixed with protein, aggregates were formed in both case of Con A and RCA120, indicating nonspecific binding. In fluorescent spectra, a decrease in the fluorescent intensity of the supernatant was observed (Figure 4B) due to the specific binding of protein to SGNPs. Thus, SFNPs containing ZAIS/ZnS NPs are applicable for both visual and fluorescent detection of sugar chain–protein interaction, the same as SFNPs containing CdTe/CdS.

Cellular Uptake of SFNPs. Following the successful binding experiments of SFNPs with proteins, the SFNPs were applied to cellular labeling and imaging. Various sugar chain-binding receptor proteins are expressed on the cell surface. The evaluation of the sugar chain-binding properties of the cell provides functional information on the cell and classifies the cell type. In the binding experiments, 3 kinds of cell lines, a human acute monocytic leukemia cell line (THP-1), a murine macrophage cell line (J774.A1), and a human hepatic carcinoma cell line (HepG2), and 6 kinds of SFNPs, α Glc-SFNP, β Gal-SFNP, α GlcNAc-SFNP, α Man-SFNP (FNPs with immobilized 4), SA α 2-3Gal-SFNP (FNPs with immobilized 5), and SA α 2-6Gal-SFNP (FNPs immobilizing 6) were used. The results of flow cytometry analysis are shown in Figure 5. Mean fluorescence intensity (MFI) was calculated from

fluorescence intensity per cell. The relative MFI value was calculated based on the value when cells were incubated without SFNPs. After 3 h of incubation, different cellular uptake of SFNPs was observed on the basis of the sugar-chain type. α Glc-SFNPs were found to bind to all 3 types of cell lines. This binding may occur by the interaction with the glucose transporter, since cells express the protein on the surface to take up glucose as an energy source.⁶² In the binding analysis with THP-1 cells, the SFNPs, except those with α Glc, showed low affinity compared to that seen with other cells. THP-1 cells are known to be immature hematopoietic cells and may not express enough amounts of sugar-binding receptors. On the other hand, J774.A1 cells, mature macrophage cells, showed high binding affinities for all the SFNPs. Mature macrophage cells are known to express various sugar-chain binding receptors such as mannose-binding protein (MBP),⁶³ galectin (galactose-binding protein),^{64,65} and sialoadhesin (sialic acid-binding protein).^{66,67} The two former receptors are involved in the phagocytotic clearance of microorganisms. The latter is related to their migration and infiltration. In the case of HepG2 cells, β Gal-SFNP predominantly bound to the cells. Hepatic cells normally express asialoglycoprotein receptor,^{68–71} which recognizes the terminal galactose moiety to remove asialogly-




Figure 6. Confocal laser scanning microscopic imaging of HepG2 cells. Overlay images (top panel, A–G) and fluorescence images (lower panel H–N). HepG2 cells were incubated without SFNPs (A and H) and with α Glc-SFNPs (B and I), α GlcNAc-SFNPs (C and J), β Gal-SFNPs (D and K), SA α 2–3Gal-SFNPs (F and M), or SA α 2–6Gal-SFNPs (G and N).




Figure 7. MTT assay for SFNPs. HepG2 cells were incubated with ZAIS/ZnS NPs (A) or CdTe/CdS QDs (B). The nanoparticle concentration was in the range of 5 μ g/mL to 50 μ g/mL (left to right).

coproteins. On the other hand, the binding intensity of the cells incubated at 4 $^{\circ}$ C was significantly decreased compared with cells incubated at 37 $^{\circ}$ C. These results indicate that SFNPs not only bound to the cell surface but were also internalized into the cells by endocytosis. Confocal laser scanning imaging for HepG2 cells yielded results similar to that of fluorescent-activated cell sorting (FACS) analysis, which showed that α Glc-SFNP and β Gal-SFNP were predominantly taken up while α GlcNAc-SFNP, SA α 2–3Gal-SFNP, and SA α 2–6Gal-SFNP were only slightly taken up (Figure 6). Thus, our prepared SFNPs are useful for the analysis and imaging of cells on the basis of sugar chain–protein interactions, and can be applicable to cell profiling.

Cytotoxicity Assay of SFNPs. The cytotoxic activity of SFNPs was evaluated by the MTT assay and morphological

analysis. In this assay, HepG2 cells were used. CdTe/CdS QDs were used for comparing cytotoxicity. In addition, to investigate the effect of capping agents, three kinds of capping agents, 1, 2, and TGA, were used. TGA-capped CdTe/CdS QDs and CdTe/CdS SFNPs were prepared according to our previous method.⁴⁹ The results of the MTT assay after 24 h incubation are shown in Figure 7. Interestingly, the metabolic activity of cells treated with ZAIS/ZnS NPs was similar to that of untreated cells (Figure 7A). The morphology of cells treated with ZAIS/ZnS SFNPs was also the same as that of untreated cells (Figure 8D and E). These data indicate that ZAIS/ZnS NPs were nontoxic in the concentration range of 5–50 μ g/mL. On the other hand, treatment with CdTe/CdS SFNPs dramatically decreased metabolic activity (Figure 7B), although capping of the QDs with sugar-chain–ligand conjugates such as




Figure 8. Microscopic images of HepG2 incubated for 24 h without SFNPs (A), with 5 µg/mL of CdTe/CdS βGal-SFNPs (B), with 50 µg/mL of CdTe/CdS βGal-SFNPs (C), with 5 µg/mL of ZAIS/ZnS βGal-SFNPs (D), and with 50 µg/mL of ZAIS/ZnS βGal-SFNPs (E).

1 and 2 slightly suppressed the cytotoxicity of CdTe/CdS QDs. In the morphological study, cells treated with CdTe/CdS SFNPs showed shrinkage, exhibiting cytotoxicity that may be caused by Cd²⁺ ions.³⁸ Thus, our newly developed ZAIS/ZnS SFNPs appear to be highly promising tools for in vitro and in vivo cell analysis because of their negligible cytotoxicity.

In this study, we successfully synthesized cadmium-free SFNPs containing low-toxicity ZAIS/ZnS NPs as the core and demonstrated their usefulness in the visual and fluorescent detection of sugar-chain–protein interactions, as well as in cellular imaging. The sugar-chain–ligand conjugate was easily immobilized onto the ZAIS NP surface by a simple ligand exchange reaction and could be applied to various sugar-chain–ligand conjugates. The binding interaction of the SFNPs with lectin was detected visually and spectroscopically. In flow cytometry analysis and cellular imaging, the binding properties of the SFNPs were diverse depending on the cell type, which may have great potential for profiling cells based on their sugar-chain binding properties. The results of the cytotoxicity assay showed that ZAIS/ZnS SFNPs were less toxic than CdTe/CdS SFNPs. Thus, our developed SFNPs are environmentally friendly compared with other cadmium-based semiconductor NPs and are likely to prove significantly useful for investigating various sugar-chain functions.

AUTHOR INFORMATION

Corresponding Authors

*TEL: (+81)99-285-7843, FAX: (+81)99-285-7856, E-mail: wakao@eng.kagoshima-u.ac.jp.

*TEL and FAX: (+81)99-285-8369.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The present study was financially supported in part by grants from Japan Science and Technology Agency (Evolutionally venture program V07-05 to Y.S., CREST to Y.S., Research for

Promoting Technological Seeds 16-057 to M.W., A-STEP AS242Z02646P to M.W.).

REFERENCES

- (1) Varki, A. (1993) Biological roles of oligosaccharides: all of the theories are correct. *Glycobiology* 3, 97–130.
- (2) Opdenakker, G., Rudd, P. M., Ponting, C. P., and Dwek, R. A. (1993) Concepts and principles of Glycobiology. *FASEB J.* 7, 1330–1337.
- (3) Park, S., and Shin, I. (2002) Fabrication of carbohydrate chips for studying protein-carbohydrate interactions. *Angew. Chem., Int. Ed.* 41, 3180–3182.
- (4) Wang, D., Liu, S., Trummer, B. J., Deng, C., and Wang, A. (2002) Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. *Nat. Biotechnol.* 20, 275–281.
- (5) Fukui, S., Feizi, T., Galustian, C., Lawson, A. M., and Chai, W. (2002) Oligosaccharide microarrays for high-throughput detection and specificity assignments of carbohydrate-protein interactions. *Nat. Biotechnol.* 20, 1011–1017.
- (6) Fazio, F., Bryan, M. C., Blixt, O., Paulson, J. C., and Wong, C.-H. (2002) Synthesis of sugar arrays in microtiter plate. *J. Am. Chem. Soc.* 124, 14397–14402.
- (7) Mann, D. A., Kanai, M., Maly, D. J., and Kiessling, L. L. (1998) Probing low affinity and multivalent interactions with surface plasmon resonance: ligands for concanavalin A. *J. Am. Chem. Soc.* 120, 10575–10582.
- (8) Horan, N., Yan, L., Isobe, H., Whitesides, G. M., and Kahne, D. (1999) Nonstatistical binding of a protein to clustered carbohydrates. *Proc. Natl. Acad. Sci. U.S.A.* 96, 11782–11786.
- (9) Oyeleran, O., and Glidersleeve, J. C. (2009) Glycan arrays: recent advances and future challenges. *Curr. Opin. Chem. Biol.* 13, 406–413.
- (10) Hase, S., Ibuki, T., and Ikenaka, T. (1984) Reexamination of the pyridylamination used for fluorescence labeling of oligosaccharides and its application to glycoproteins. *J. Biochem.* 95, 197–203.
- (11) Anumula, K. R. (2006) Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. *Anal. Biochem.* 350, 1–23.
- (12) Reddington, M. V. (1998) New glycoconjugated cyanine dyes as fluorescent labeling reagents. *J. Chem. Soc., Perkin Trans.* 143–147.

- (13) Gege, C., Oscarson, S., and Schmidt, R. R. (2001) Synthesis of fluorescence labeled sialyl lewis(x) glycosphingolipids. *Tetrahedron Lett.* 42, 377–380.
- (14) de la Fuente, J. M., Barrientos, A. G., Rojas, T. C., Rojo, J., Cañada, J., Fernández, A., and Penadés, S. (2001) Gold glyconanoparticles as water-soluble polyvalent models to study carbohydrate interactions. *Angew. Chem., Int. Ed.* 40, 2258–2261.
- (15) Osaki, F., Kanamori, T., Sando, S., Sere, T., and Aoyama, Y. (2004) A quantum dot conjugated sugar ball and its cellular uptake. on the size effects of endocytosis in the subviral region. *J. Am. Chem. Soc.* 126, 6520–6521.
- (16) Sun, X.-L., Cui, W., Haller, C., and Chaikof, E. L. (2004) Site-specific multivalent carbohydrate labeling of quantum dots and magnetic beads. *ChemBioChem* 5, 1593–1596.
- (17) de la Fuente, J. M., and Penadés, S. (2005) Glyco-quantum dots: a new luminescent system with multivalent carbohydrate display. *Tetrahedron: Asymmetry* 16, 387–391.
- (18) Robinson, A., Fang, J.-M., Chou, P.-T., Liao, K.-W., Chu, R.-M., and Lee, S.-J. (2005) Probing lectin and sperm with carbohydrate-modified quantum dots. *ChemBioChem* 6, 1899–1905.
- (19) Babu, P., Sinha, S., and Suroli, A. (2007) Sugar-quantum dot conjugates for selective and sensitive detection of lectins. *Bioconjugate Chem.* 18, 146–151.
- (20) Niikura, K., Nishio, T., Akita, H., Matsuo, Y., Kamitani, R., Kogure, K., Harashima, H., and Ijio, K. (2007) Accumulation of O-GlcNAc-displaying CdTe quantum Dots in cells in the presence of ATP. *ChemBioChem* 8, 379–384.
- (21) Kikkeri, R., Lepenies, B., Adibekian, A., Laurino, P., and Seeberger, P. H. (2009) In vivo imaging and in vitro liver targeting with carbohydrate capped quantum dots. *J. Am. Chem. Soc.* 131, 2110–2112.
- (22) Marradi, M., Martín-Lomas, M., and Penadés, S. (2010) Glyconanoparticles: polyvalent tools to study carbohydrate-based interactions. *Adv. Carbohydr. Chem. Biochem.* 64, 211–290.
- (23) Varki, A., and Marth, J. (1995) Oligosaccharides in vertebrate development. *Semin. Dev. Biol.* 6, 127–138.
- (24) Gabius, H.-J., André, S., Kaltner, H., and Siebert, H.-C. (2002) The sugar code: functional lectinomics. *Biochim. Biophys. Acta* 1572, 165–177.
- (25) Sharon, N., and Lis, H. (2004) History of lectins: from hemagglutinins to biological recognition molecules. *Glycobiology* 14, 53R–62R.
- (26) Ilyin, S. E., Belkowski, S. M., and Plata-Salamán, C. R. (2004) Biomarker discovery and validation: technologies and integrative approaches. *TRENDS Biotechnol.* 22, 411–416.
- (27) Rifai, N., Gillette, M. A., and Carr, S. A. (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nat. Biotechnol.* 24, 971–983.
- (28) Nagano, K., Yoshida, Y., and Isobe, T. (2008) Cell surface biomarkers of embryonic stem cells. *Proteomics* 8, 4025–4035.
- (29) Tateno, H., Uchiyama, N., Kuno, A., Togayachi, A., Sato, T., Narimatsu, H., and Hirabayashi, J. (2007) A novel strategy for mammalian cell surface glycome profiling using lectin microarray. *Glycobiology* 17, 1138–1146.
- (30) Toyoda, M., Yamazaki-Inoue, M., Itakura, Y., Kuno, A., Ogawa, T., Yamada, M., Akutsu, H., Takahashi, Y., Kanzaki, S., Narimatsu, H., Hirabayashi, J., and Umezawa, A. (2011) Lectin microarray analysis of pluripotent and multipotent stem cells. *Genes Cells* 16, 1–11.
- (31) Jeong, H. H., Kim, Y. G., Jang, S. C., Yi, H., and Lee, C. S. (2012) Profiling surface glycan on live cells and tissues using quantum dot-lectin nanoconjugates. *Lab Chip* 12, 3290–3295.
- (32) Nishijima, Y., Toyoda, M., Yamazaki-Inoue, M., Sugiyama, T., Miyazawa, M., Muramatsu, T., Nakamura, K., Narimatsu, H., Umezawa, A., and Mikami, M. (2012) Glycan profiling of endometrial cancers using lectin microarray. *Genes Cells* 17, 826–836.
- (33) Alivisatos, A. P. (1996) Semiconductor clusters, nanocrystals, and quantum dots. *Science* 271, 933–937.
- (34) Bruchez, M., Moronne, M., Gin, P., Weiss, S., and Alivisatos, A. P. (1998) Semiconductor nanocrystals as fluorescent biological labels. *Science* 281, 2031–2016.
- (35) Chan, W. C. W., and Nie, S. M. (1998) Quantum dot bioconjugates for ultrasensitive nonisotopic detection. *Science* 281, 2016–2018.
- (36) Akerman, M. E., Chan, W. C. W., Laakkonen, P., Bhatia, S. N., and Ruslahti, E. (2002) Nanocrystal targeting in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 99, 12617–12621.
- (37) Walling, M. A., Novak, J. A., and Shepard, J. R. E. (2009) Quantum dots for live cell and in vivo imaging. *Int. J. Mol. Sci.* 10, 441–491.
- (38) Ipe, B. I., Lehnig, M., and Niemeyer, C. M. (2005) On the generation of free radical species from quantum dots. *Small* 1, 706–709.
- (39) Hardman, R. (2006) A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. *Env. Health Persp.* 114, 116–172.
- (40) Chang, E., Thekkekk, N., Yu, W. W., Colvin, V. L., and Drezek, R. (2006) Evaluation of quantum dot cytotoxicity based on intracellular uptake. *Small* 2, 1412–1417.
- (41) Chang, S.-Q., Dai, Y.-D., Kang, B., Han, W., Mao, L., and Chen, D. (2009) UV-enhanced cytotoxicity of thiol-capped CdTe quantum dots in human pancreatic carcinoma cells. *Toxicol. Lett.* 188, 104–111.
- (42) Rzigalinski, B. A., and Strobl, J. S. (2009) Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. *Toxicol. Appl. Pharmacol.* 238, 280–288.
- (43) Ballou, B., Lagerholm, B. C., Ernst, L. A., Bruchez, M. P., and Waggoner, A. S. (2004) Noninvasive imaging of quantum dots in mice. *Bioconjugate Chem.* 15, 79–86.
- (44) Hoshino, A., Fujioka, K., Oku, T., Suga, M., Sasaki, F. Y., Ohta, T., Yasuhara, M., Suzuki, K., and Yamamoto, K. (2004) Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification. *Nano Lett.* 4, 2163–2169.
- (45) Shiohara, A., Hoshino, A., Hanaki, K., Suzuki, K., and Yamamoto, K. (2004) On the cytotoxicity of quantum dots. *Microbiol. Immunol.* 48, 669–675.
- (46) Kim, J., Park, Y., Yoon, T. H., Yoon, C. S., and Choi, K. (2010) Phototoxicity of CdSe/ZnSe quantum dots with surface coatings of 3-mercaptopropionic acid or tri-*n*-octylphosphine oxide/gum arabic in *Daphnia magna* under environmentally relevant UV-B light. *Aquatic Toxicol.* 97, 116–124.
- (47) Suda, Y., Arano, A., Fukui, Y., Koshida, S., Wakao, M., Nishimura, T., Kusumoto, S., and Sobel, M. (2006) Immobilization and clustering of structurally defined oligosaccharides for sugar chips: an improved method for surface plasmon resonance analysis of protein–carbohydrate interactions. *Bioconjugate Chem.* 17, 1125–1135.
- (48) Zhang, X., Nakamura-Tsuruta, S., Haruyama, M., Yokoyama, R., Nagatomo, M., Wakao, M., Nakajima, K., Aoyama, K., Okuno, T., Morikawa, S., Hiroi, S., Kase, T., Nose, H., Nishi, J., Okamoto, M., Baba, M., and Suda, Y. (2012) Super sensitive detection of viruses using sugar-chain immobilized gold nano-particles (SGNPs). *Polym. Prepr.* 53, 671–672.
- (49) Shinchi, H., Wakao, M., Nakagawa, S., Mochizuki, E., Kuwabata, S., and Suda, Y. (2012) Stable sugar-chain immobilized fluorescent nano-particle for probing lectin and cells. *Chem.-Asian J.* 7, 2678–2682.
- (50) Torimoto, T., Adachi, T., Okazaki, K., Sakurao, M., Shibayama, T., Ohtani, B., Kudo, A., and Kuwabata, S. (2007) Facile synthesis of ZnS-AgInS₂ solid solution nanoparticles for color-adjustable luminophore. *J. Am. Chem. Soc.* 129, 12388–12389.
- (51) Torimoto, T., Ogawa, S., Adachi, T., Kameyama, T., Okazaki, K., Shibayama, T., Kudo, A., and Kuwabata, S. (2010) Remarkable photoluminescence enhancement of ZnS-AgInS₂ solid solution nanoparticles by postsynthesis treatment. *Chem. Commun.* 46, 2082–2084.

- (52) Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immun. Methods.* 65, 55–63.
- (53) Kuzuya, T., Tai, Y., Yamamuro, S., and Sumiyama, K. (2005) Synthesis of copper and zinc sulfide nanocrystals via thermolysis of the polymetallic thiolate cage. *Sci. Technol. Adv. Mater.* 6, 84–90.
- (54) Castro, S. L., Bailey, S. G., Raffaele, R. P., Banger, K. K., and Hepp, A. F. (2003) Nanocrystalline chalcopyrite materials (CuInS_2 and CuInSe_2) via low-temperature pyrolysis of molecular single-source precursors. *Chem. Mater.* 15, 3142–3147.
- (55) Li, L., Daou, T. J., Texier, I., and Kim, T. T. (2009) Highly luminescent $\text{CuInS}_2/\text{ZnS}$ core/shell nanocrystals: cadmium-free quantum dots for in vivo imaging. *Chem. Mater.* 21, 2422–2429.
- (56) Pons, T., Pic, E., Lequeux, N., Cassette, E., Bezdetnaya, L., Guillemin, F., Marchal, F., and Dubertret, B. (2010) Cadmium-free $\text{CuInS}_2/\text{ZnS}$ quantum dots for sentinel lymph node imaging with reduced toxicity. *ACS Nano* 4, 2531–2538.
- (57) Matsumoto, T., Maenosono, S., and Yamaguchi, Y. (2004) Organometallic synthesis of InP quantum dots using tris-(dimethylamino)phosphine as a phosphorus source. *Chem. Lett.* 33, 1492–1493.
- (58) Li, C., Ando, M., Enomoto, H., and Murase, N. (2008) Highly luminescent water-soluble InP/ZnS nanocrystals prepared via reactive phase transfer and photochemical processing. *J. Phys. Chem. C* 112, 20190–20199.
- (59) Roe, J. H. (1955) The determination of sugar in blood and spinal fluid with anthrone reagent. *J. Biol. Chem.* 212, 335–343.
- (60) Prasuhn, E. D., Deschamps, J. R., Susumu, K., Stewart, M. H., Boeneman, K., Blanco-Canosa, J. B., Dawson, P. E., and Medintz, I. L. (2010) Polyvalent display and packing of peptides and proteins on semiconductor quantum dots: predicted versus experimental results. *Small* 6, 555–564.
- (61) Nakamura-Tsuruta, S., Kishimoto, Y., Nishimura, T., and Suda, Y. (2008) One-step purification of lectins from Banana pulp using sugar-immobilized gold nano-particles. *J. Biochem.* 143, 833–839.
- (62) Wood, I. S., and Trayhurn, P. (2003) Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. *Br. J. Nutr.* 89, 3–9.
- (63) Stahl, P. D. (1992) The mannose receptor and other macrophage lectins. *Curr. Opin. Immunol.* 4, 49–52.
- (64) Sato, S., and Hughes, R. C. (1994) Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. *J. Biol. Chem.* 269, 4424–4430.
- (65) Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., and Liu, F.-T. (2003) Critical role of galectin-3 phagocytosis by macrophages. *J. Clin. Invest.* 112, 389–397.
- (66) Crocker, P. R., Mucklow, S., Bouckson, V., McWilliam, A., Willis, A. C., Gordon, S., Milon, G., Kelm, S., and Bradfield, P. (1994) Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 immunoglobulin-like domains. *EMBO J.* 13, 4490–4503.
- (67) Jones, C., Virji, M., and Crocker, R. (2003) Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake. *Mol. Microbiol.* 49, 1213–1225.
- (68) Baenziger, J. U., and Fiete, D. (1980) Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes. *Cell* 22, 611–620.
- (69) Ashwell, G., and Harford, J. (1982) Carbohydrate-specific receptors of the liver. *Annu. Rev. Biochem.* 51, 531–554.
- (70) Braun, J. R., Willnow, T. E., Ishibashi, S., Ashwell, G., and Herz, J. (1996) Sugar chains, lipids, and other natural products. *J. Biol. Chem.* 271, 21160–21166.
- (71) Raju, T. S., Briggs, J. B., Chamow, S. M., Winkler, M. E., and Jones, A. J. S. (2001) Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residue. *Biochemistry* 40, 8868–8876.